Cosmos Holdings

COSM

Market cap $12.8M

Doc Pharma financial profile: approximately $24 million asset base, approximately $6.7 million in average annual revenue and approximately $3.2 million in average annual gross profit. Immediately accretive: expected to support margin expansion, profitability, and cash flow.

CHICAGO, June 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has secured a three-year contract manufacturing agreement with Verisfield S.A. (“Verisfield”), a specialty pharmaceutical company focused on the development and marketing of generic and differentiated pharmaceutical products across multiple therapeutic categories.

Key Highlights Record revenue, continued momentum: all-time high $65.3M in FY2025; strongest-ever Q1 2026, carrying into Q2. Record operational momentum: CosmoFarm wholesale distribution and GMP-certified Cana contract manufacturing both delivering record volumes.

CHICAGO, June 09, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has inaugurated a new, state-of-the-art capsule production line and secured an additional contract manufacturing agreement with Provident Pharmaceuticals ("Provident"), a specialty pharmaceutical company focused on the commercialization and marketing of niche and legacy pharmaceutical products and medical devices in specific therapeutic areas. Under the new five-year agreement, Cana will manufacture 385,000 units of CERTORUN® (sertraline hydrochloride) over the five-year period, at an annual production volume of 77,000 units.

KEY HIGHLIGHTS Cana Laboratories, Cosmos Health's wholly owned subsidiary, acquires international patent application WO2025108566A1 from Cloudpharm P.C. Patent protection being pursued at national and regional levels across key international markets Technology supports next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare product development Expands nanotechnology investment initiatives, leveraging Cana Laboratories' European GMP-certified manufacturing capabilities Aligned with the Company's broader strategy of expanding its IP portfolio, strengthening vertical integration, and driving long-term shareholder value CHICAGO, June 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A.

Oliv18™ expands the 18 Series with a USDA and EU organic certified, 100% solvent-free, whole olive polyphenol formulation from the Moroccan Saharan desert Hydroxytyrosol — the key active in Oliv18™ — is the highest ORAC polyphenol A single 250 mg daily dose meets EFSA's 5 mg/day hydroxytyrosol minimum dose for protection against LDL oxidation A single daily dose equivalent to approximately 11 teaspoons of good quality extra virgin olive oil — compared to an average of half a teaspoon per day in the U.S. Targeting the multibillion cardiovascular health and antioxidant markets, initially in the United States and globally thereafter — within a combined global market landscape projected to exceed $33 billion by 2035 CHICAGO, June 05, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the U.S. launch of Oliv18™, further expanding its science-driven 18 Series nutraceutical platform into cardiovascular and antioxidant categories. Scientific Background Oliv18™ is formulated with a whole olive polyphenol extract derived from the fruit and leaf of olive trees cultivated in the Moroccan stretch of the Saharan Desert.

CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its proprietary brand, Sky Premium Life, is now available for shipment across all 27 European Union Member States through Skroutz, significantly expanding the brand's international reach. A total of 96 Sky Premium Life products are now accessible to consumers across all 27 European Union Member States through Skroutz, with shipments reaching key markets across Western Europe, Northern Europe, and Central and Eastern Europe.

Company identifies real estate, digital assets, and marketable securities, among others, as potential sources of liquidity — with a combined value of approximately $20 million Proceeds could fund a meaningful acquisition or eliminate debt entirely Company remains fully committed to its core healthcare operations CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced it is exploring the monetization of non-core assets, having identified approximately $20 million in assets that can be converted to liquidity without impacting the Company's operational capabilities. The Company is fully committed to its core healthcare operations and views these assets as non-core in the sense that they can be monetized to strengthen the balance sheet, fund strategic initiatives, and close the gap between intrinsic value and current market valuation.

Cosmos Holdings Inc. (NASDAQ:COSM)(dba Cosmos Health) is entering the animal health market, extending its C-Scrub brand into the veterinary space after the product passed testing against European standards, the company said Monday. The move takes C-Scrub, one of the company's branded products, into veterinary applications following what Cosmos described as successful European standard testing.

CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the extension of its C-Scrub antimicrobial wash brand into the veterinary and animal health sector through the planned launch of a veterinary formulation of C-Scrub Wash 4%, marking the Company's first entry into the animal health market. The Company intends to launch the veterinary formulation in the United Kingdom, where C-Scrub is already an established and commercially active human-use brand, with broader international expansion to follow.